Thursday , May 25 2017
Home / Pulmonary Diseases

Pulmonary Diseases

Two Biomarkers Appear to Predict Course of Idiopathic Pulmonary Fibrosis

ATS 2017, WASHINGTON, DC — Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference. T-cells marshal the body’s …

Read More »

FDA Expands Approval of Vertex’s Kalydeco to Treat Additional Mutations of Cystic Fibrosis

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO® (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. …

Read More »

AstraZeneca and Pieris Enter up to $2.1 Billion Deal in Respiratory Drug Collaboration

AstraZeneca today announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering …

Read More »

New Study Reveals Payers and Hospitals Can Save Millions in Readmission Costs, Hospitalization Rates for COPD Patients

AMSTERDAM, April 21, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA) today announced results1 from a recent study showing significant decreases in both hospital and payer costs and hospitalization rates for severe chronic obstructive pulmonary disease (COPD)2 patients. The study entitled, “Cost Savings from Reduced Hospitalizations with Use of …

Read More »

Corbus Pharmaceuticals Reports Positive Topline Data from its Cystic Fibrosis Study

NORWORD, MA — (Marketwired) — 03/30/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum (fka JBT-101 or Resunab) …

Read More »

Vertex’s Cystic Fibrosis Combo Meets Primary Endpoints in Two Late-Stage Studies

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from two Phase 3 studies of the tezacaftor (VX-661) / ivacaftor combination treatment that showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in people with cystic fibrosis (CF) ages 12 and older …

Read More »

Genetics Reveal Mysteries of Hard-to-Treat Bacterial Infection in Cystic Fibrosis

New UBC research on bacteria that cause major problems for those with cystic fibrosis reveals clues as to how it proliferates for so long in the lungs and offers new ideas for treatments to explore. “Someone with cystic fibrosis has about one less teaspoon of water in the mucous in …

Read More »

Vertex Acquires Cystic Fibrosis Candidate from Concert Pharmaceuticals in Potential $250 Million Deal

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE). CTP-656 is an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that has the potential to be used as part of future once-daily combination …

Read More »

PTC Therapeutics Discontinues Ataluren Program After Failed Phase 3 Trial in Nonsense Mutation Cystic Fibrosis

SOUTH PLAINFIELD, N.J., March 2, 2017 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the Ataluren Confirmatory Trial (ACT CF) in nonsense mutation cystic fibrosis (nmCF) did not achieve its primary or secondary endpoints. Ataluren was generally well tolerated and ACT CF confirmed a favorable safety profile for ataluren, …

Read More »

Concert Pharmaceuticals’ Cystic Fibrosis Candidate Receives Orphan Drug Status from the FDA

LEXINGTON, Mass.–(BUSINESS WIRE)– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for CTP-656, Concert’s next generation CFTR potentiator being developed for the treatment of cystic fibrosis. In December 2016, Concert initiated a Phase 2 trial in the U.S. …

Read More »